Neal Andrews
Co-Founder | CEO | President
Neal W. Andrews is President and CEO of DermDefense, Inc. and 1997 Holding, Inc. Mr. Andrews is a disabled veteran, focused on serving his country with this honorable mission of gaining approval for SM-1997 to be used in the treatment of sulfur mustard-induced skin injuries.
His extensive experience in military and scientific research includes established relationships with a variety of agencies, including the Defense Threat Reduction Agency (DTRA), Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), Counter Act, the U.S. Army Medical Logistics Command (USAMMA), and the US-NATO partner community.
Mr. Andrews has worked with and for the benefit of SM-1997 with a variety of key experts including the following people and organizations:
- Senior Staff of U.S. Army Medical Research Institute of Chemical Defense (USAMRICD)
- Senior Staff of USAMMA at Fort Detrick
- Senior Staff Countermeasures Against Chemical Threats (CounterACT) Program
- Senior Staff at the National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services (HHS)
- Senior Staff at BARDA
- Senior Staff at MRI Global
- Senior Staff at Battelle Biomedical
- Senior Staff of Bundeswehr, Institute of Pharmacology and Toxicology (German Army) Munchen, Germany
- Team members at the Institute for Biological Research (IIBR)
Mr. Andrews has gathered together an outstanding team for DermDefense that includes an FDA regulatory team of experts, a science team, and a variety of international consultants to ensure that DermDefense secures new drug approval by the FDA, including a coveted Priority Review Voucher.
Mr. Andrews has been integrally involved in the development of the protocols that provide the basis for DermDefense Inc’s current project and will continue in this role to help develop research protocols, methodology, formulation strength, and will review and analyze the data results through final FDA approval.
